General Partners


» Ammar Hanafi
» Michael Hunkapiller
» Doug Kelly, MD
» Dan Rubin
» John Shoch
» Craig Taylor

Ammar Hanafi


Ammar H. Hanafi joined Alloy Ventures as a general partner in 2005. At Alloy, he focuses on investments in cloud computing infrastructure and services.

Operating experience
Ammar previously served as Vice President of New Business Ventures at Cisco Systems and Vice President of Corporate Business Development prior to that, where he was responsible for Cisco's acquisitions, acquisition integration, investment, and joint venture activity on a global basis. He joined Cisco in 1997 as a member of the Corporate Business Development Group. During his tenure at Cisco, he helped the company complete over 100 investment and M&A transactions, including 50 acquisitions and over $750 million in venture capital investments. Ammar received a BS in Applied and Engineering Physics from Cornell University (1988) and an MBA from Stanford University (1995).

Current board seats
Ammar serves on the board of directors of Hightail, Mavenir Systems (NASDAQ: MVNR), Cortina Systems, GigaOM and Agari. He also serves on the board of directors of American Leadership Forum Silicon Valley (ALF), a non-profit organization.

Michael Hunkapiller


Michael Hunkapiller joined Alloy in 2004 after 30-year career in bioscience research and executive management in the life science industry. He focuses on investments in life science research tools and instrumentation, as well as clinical diagnostics.

Operating experience
A renowned scientist, entrepreneur and life science industry executive, Mike brings a unique mix of experience to Alloy. He spent 21 years at Applied Biosystems (NASDAQ: LIFE), which he co-founded and helped grow from startup to almost $2 billion in annual revenues supplying instrument and reagent systems for life science research. At ABI, he held several positions, most recently president and general manager. He was also a founder of ABI's sister company Celera Genomics (NASDAQ: CRA) and senior vice president of Applera Corp. (their parent company). Prior to joining ABI, Mike was a senior research fellow in the Division of Biology at the California Institute of Technology. He has authored more than 100 scientific publications, is an inventor on more than two dozen patents and has served on the editorial boards of several scientific journals. He has received several awards for his contributions to life science research, especially for his invention of the automated Gene and Protein Sequencer used to sequence the human genome. He was elected in 2008 to the National Academy of Engineering for his life-long dedication to the human genome mapping project and the field of comparative genetics. He received a B.S. in Chemistry from Oklahoma Baptist University in 1970 and a Ph.D. in Chemical Biology from the Division of Chemistry and Chemical Engineering at Caltech in 1974.

Current board seats
Mike serves on the board of directors of Pacific Biosciences (NASDAQ: PACB), NuGEN and RainDance Technologies.

Past Board Seats
Mike served on the board of Fluidigm which completed its IPO in February, 2011 (NASDAQ: FLDM), and Verinata Health which was acquired in January 2013 by Illumina (NASDAQ: ILMN).

Doug Kelly, MD


Doug Kelly has worked with the partners of Alloy Ventures since 1993 and was a founding member of the firm. He currently focuses on investments in medical device companies.

Operating experience
Trained as a physician, Doug is a long-time venture investor with 20 years of experience in bridging the needs of the business and medical communities with novel applications of technology to create world-class companies. Prior to joining Alloy Ventures, he worked for two European venture capital firms, in business development at Ligand Pharmaceuticals, and as an independent consultant. Additionally, Doug teaches "Business 16 Financing The Startup" at Stanford Univeristy. Doug received a BA in Biochemistry and Cell Biology from the University of California at San Diego (1983), an MD from the Albert Einstein College of Medicine in 1988, and an MBA from Stanford University (1990).

Current board seats
Doug serves on the board of directors of Aegea,
CoAlign Innovations
, and Restoration Robotics.

Past Board Seats
Doug has invested in many leading medical device and biotech companies, and previously served on the boards of Sapient Health Network (acquired by WebMD/Healtheon in 1999), Camitro (acquired by Arqule in 2001), Fusion Medical (acquired by Baxter in 2002), Integrated Biosystems (acquired by Stedim SA in 2004), Adiana (acquired by Cytyc/Hologic in 2007), Pharsight (acquired by Tripos in 2008), Barrx Medical (acquired by Covidien in January 2012), Cameron Health (acquired by Boston Scientific in June 2012), Crux Biomedical (acquired by Volcano Corp. in December 2012),

Daniel Rubin


Daniel I. Rubin joined Alloy Ventures in 1999 after a 15-year career in business development, marketing and sales at leading technology companies. At Alloy, he focuses on investments in semiconductors, cleantech, and software-as-a-service.

Operating experience
Before becoming a venture capitalist in 1999, Dan was a successful technology entrepreneur and also held a variety of executive-level sales, marketing and business development jobs in the IT industry. In 1991, he was a co-founder of Artisan Components and served as the initial VP of sales and marketing. He was the VP of business development through the company’s initial public offering in 1998. The company was later acquired by ARM Ltd. for $1 billion.

Prior to Artisan Components, Dan worked at semiconductor capital equipment company Ultratech Stepper in many roles, including director of product marketing and managing director of Asian operations. He received a BA in Physics from Pomona College (1982).

Current board seats
Dan serves on the board of directors of Ensenda, Molecular Imprints, Gradient Design Automation, Scifiniti, and Teradici.

Past Board Seats
Dan previously served on the board of directors for Ciranova (acquired by Synopsys in 2012), Integrated Materials (acquired by Ferrotec in 2010) and as a board observer at Ellie Mae, which completed its IPO in April, 2011 (NASDAQ: ELLI).

John Shoch


John F. Shoch, PhD, became a venture capitalist in 1985, first working with Craig Taylor to manage venture investments at Asset Management Associates, and then co-founding Alloy Ventures in 1996. At Alloy, he focuses on investments in enterprise software, communications infrastructure, semiconductors and all aspects of the Internet.

Operating experience
Before becoming a venture capitalist, John worked as a computer scientist, technology executive and inventor. He gained deep hands-on, operational experience at Xerox, which he joined in 1971. For many years, he worked at the Xerox Palo Alto Research Center (PARC), where he helped develop the Ethernet, a local area network system. In 1980, he became the assistant to the CEO of Xerox. In 1982, John became President of the Office Systems Division, developing networked office systems derived from Xerox PARC research. John received a BA (1971) in Political Science, an MS (1977), and a PhD (1979) in Computer Science, all from Stanford.

Past Board Seats
John was previously a director of semiconductor firm Conductus, which was acquired by Superconductor Technologies Inc. in 2002; and Remedy, a leading enterprise software company that completed a successful IPO on NASDAQ in 1995 and was later acquired by Peregrine Systems. John also served on the board of Polimetrix (acquired by YouGov in 2007) and MontaVista (acquired by Cavium Networks in 2009) and Knowledge Networks (acquired by GfK in 2012).

Craig Taylor


Craig C. Taylor has been an active venture capitalist since 1977, and co-founded Alloy Ventures with John Shoch in 1996. At Alloy, he focuses on investments in laboratory instrumentation, diagnostics and cleantech, especially green-focused companies that sit at the intersection of biotech, nanotech and IT.

Operating experience
Craig is a veteran venture capital investor with a focus on technology transfer from leading research institutions. Before co-founding Alloy Ventures, he worked at Asset Management Co., which he joined in 1977. Previously, Craig worked in the Office of Technology Licensing at Stanford University from 1975 to 1977. He is a past member of the Board of Directors of the National Venture Capital Association, and serves on the Board of Advisors of the MIT/Stanford Venture Laboratory. He earned a BS (1972) and an MS (1974) in physics from Brown University, and an MBA from Stanford (1977).

Current board seats
Craig serves on the board of directors of Labcyte, Zyomyx, and KFx Medical.

Past board seats
Craig has led successful investments in, and served on the boards of, dozens of leading life science companies. He was a founding board member of Applied Biosystems, the pioneering biotechnology company founded in 1981 that was later became a division of Applera and was recently sold for $6.7 billion to Invitrogen Corp. He was also a founding board member of Adeza Biomedical, a woman's health company that completed a public offering on Nasdaq in 2004 and was later acquired by Cytec. He also served on the board of Lynx Therapeutics, a provider of genetic analysis tools for biological research that completed an IPO on Nasdaq in 2000, and later merged with Solexa Ltd., before it was acquired by Illumina for $600 million 2006. Craig also served on the board of ForteBio which was acquired by Pall Corporation in 2012 and on Optimedica which was acquired by Abbott in August 2013.

“For over five years, Alloy has supported the growth of our business through its visionary, strategic guidance, day-to-day tactical support and long-term capitalization. Doug Kelly has been an active participant in the management of our company and has contributed to a significantly enhanced enterprise value. We are extremely fortunate to have such a strong partner and friend to our business.”

– Greg Barrett, Chairman, President and CEO, BÂRRX Medical Inc.

“Mike Hunkapiller has been a tremendous asset as a Director. He has contributed to our market development strategies, our recruiting efforts, financing, and even our technology development plans. There are few like him in the health care industry.”

– Gajus Worthington, CEO of Fluidigm